Purchase Order 75F40120P00313
- Not listed
- The Food and Drug Administration (FDA) awarded a $22,067 firm fixed-price purchase order to 10X Genomics, Inc. for single cell sequencing library supplies. The contract, designated as a total small business set-aside, was awarded on July 26, 2019, with an ultimate completion date of August 25, 2019. Performance is to take place at 10X Genomics' headquarters in Pleasanton, California. This procurement reflects the FDA's need for advanced genomic analysis capabilities, specifically single-cell...
- This is a firm fixed price purchase order awarded by the Food and Drug Administration (FDA) to 10X Genomics, Inc., a small business contractor, for a Parallel Partitioning System, Accessory Kit, and Reagents for single cell sequencing analysis. The $67,882.25 contract is set aside for small businesses and will support the FDA's Center for Biologics Evaluation and Research's characterization of cells to be used as reference materials for next generation sequencing studies. 10X Genomics provides...
- This firm fixed-price purchase order was awarded by the Food and Drug Administration (FDA) to 10X Genomics, Inc., a life sciences technology company, for the provision of one (1) unit of a Chromium Single Cell Controller with accessories. The contract has a ceiling value of $90,382.25 and a period of performance through June 30, 2025. No set-aside designation was used for this award. 10X Genomics has previously provided specialized genomics products and services, such as kits for single-cell RNA...
- 10X Genomics, Inc., a leading biotechnology company headquartered in Pleasanton, California, received a Blanket Purchase Agreement (BPA) call valued at approximately $25K from the Office of Logistics and Acquisition Operations, with a completion date of February 25, 2027. This firm fixed price contract, awarded without set-aside designation, represents a continuation of the company's extensive federal contracting relationship as a primary supplier of advanced genomic analysis platforms and...
- This federal contract award to 10X Genomics, Inc., a biotechnology company based in Pleasanton, California, provides highly specific consumables and reagents for localizing RNA sequences within individual cells. The $12,739.00 Firm Fixed Price contract was awarded by the National Institutes of Health (NIH) Clinical Center, a civilian agency, on May 31, 2024 with a completion date of June 30, 2024. The award is not set aside for a specific business type. 10X Genomics has been awarded numerous...
- This is a $45,335.00 firm fixed price purchase order awarded by the National Institute of Environmental Health Sciences, a civilian agency, to 10X Genomics, Inc., a for-profit manufacturer headquartered in Pleasanton, California. The contract is for the delivery of epigenomics laboratory reagents to support spatial sequencing gene expression research. No set-aside was used. 10X Genomics is a leading provider of advanced genomic analysis platforms, instruments, and bioinformatics software to...
- This is a federal contract award to 10X Genomics, Inc., a biotechnology company in Pleasanton, California, for the procurement of laboratory supplies. The contract has a ceiling value of $34,810.59 and a performance period ending on September 11, 2026. The contract is a purchase order with a firm fixed-price pricing type, awarded by the National Institutes of Health (NIH) Clinical Center, a civilian agency. The contract does not have a set-aside designation. 10X Genomics is the prime...
- 10X Genomics, Inc. was awarded a $46,242.50 firm fixed price purchase order by the Department of Health and Human Services' National Institutes of Health Office of Logistics and Acquisition Operations. The contract calls for 10X Genomics to provide its genomics products and services from its Bethesda, Maryland location to support NIH's biomedical research efforts from September 2023 through September 2024. As a leading developer and manufacturer of single-cell analysis solutions, 10X Genomics...
- This is a $12,000 firm fixed price purchase order awarded by the National Institutes of Health (NIH) Clinical Center to 10X Genomics, Inc., a life sciences technology company headquartered in Pleasanton, California. The contract is not set aside and runs through July 2026. 10X Genomics will provide specialized scientific equipment, consumables, and research tools to support advanced biomedical research across various domains, including infectious diseases, cancer, neurological disorders, and...
- This is a firm fixed-price purchase order awarded by the Office of Logistics and Acquisition Operations, a civilian agency, to 10X Genomics, Inc. as the prime contractor. The $52,750.00 contract is for the delivery of 10X Genomics' products and services related to single-cell and spatial analysis applications, including specialized kits, instruments, and associated installation, training, maintenance, and support. The end date for the contract is August 8, 2025. This award is not associated with...
The U.S. Food and Drug Administration (FDA) awarded a $15,000 firm fixed price purchase order to 10X Genomics, Inc. for a Parallel Partitioning System Service Agreement on June 22, 2020, with an ultimate completion date of June 27, 2023. The contract was not designated as a set-aside and was performed at 10X Genomics' headquarters location in Pleasanton, California. 10X Genomics is a leading biotechnology company specializing in advanced genomic analysis platforms, including single-cell and spatial transcriptomics technologies that support high-resolution molecular analysis for biomedical research applications. As a registered federal contractor since 2015, 10X Genomics has established itself as a primary supplier of specialized genomic research tools across multiple federal agencies. While the company maintains significant indefinite delivery contracts with the National Institutes of Health, including a $7 million agreement with the National Institute on Aging through July 2029, this particular FDA purchase order represents a discrete engagement supporting the agency's regulatory and research operations. The company's comprehensive product portfolio, including Chromium and Xenium platforms along with associated reagents and consumables, provides critical infrastructure for federal research institutions investigating complex biological systems and disease mechanisms.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| P00005 | Close Out | ($7k) | 1/20/26 | |
| P00004 | Other Administrative Action | $0 | 7/19/22 | |
| P00003 | Exercise an Option | $7.5k | 6/22/22 | |
| P00002 | Exercise an Option | $7.5k | 5/5/21 | |
| P00001 | Other Administrative Action | $0 | 7/16/20 |